|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baldwin LA, Huang B, Miller RW, Tucker T,
Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR
and Seamon LG: Ten-year relative survival for epithelial ovarian
cancer. Obstet Gynecol. 120:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sopik V, Iqbal J, Rosen B and Narod SA:
Why have ovarian cancer mortality rates declined? Part I.
Incidence. Gynecol Oncol. 138:741–749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cuellar-Partida G, Lu Y, Dixon SC,
Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van
Nieuwenhuysen E, Vergote I, et al Australian Ovarian Cancer Study:
Assessing the genetic architecture of epithelial ovarian cancer
histological subtypes. Hum Genet. 135:741–756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Papaioannou NE, Beniata OV, Vitsos P,
Tsitsilonis O and Samara P: Harnessing the immune system to improve
cancer therapy. Ann Transl Med. 4:261–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Knutson KL, Karyampudi L, Lamichhane P and
Preston C: Targeted immune therapy of ovarian cancer. Cancer
Metastasis Rev. 34:53–74. 2015. View Article : Google Scholar :
|
|
8
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia
GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,
Casares N, et al: Calreticulin exposure dictates the immunogenicity
of cancer cell death. Nat Med. 13:54–61. 2007. View Article : Google Scholar
|
|
9
|
Tapia V, Gabler F, Muñoz M, Yazigi R,
Paredes A, Selman A, Vega M and Romero C: Tyrosine kinase A
receptor (trkA): A potential marker in epithelial ovarian cancer.
Gynecol Oncol. 121:13–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yadav L, Puri N, Rastogi V, Satpute P and
Sharma V: Tumour angiogenesis and angiogenic inhibitors: A review.
J Clin Diagn Res. 9:XE01–XE05. 2015.PubMed/NCBI
|
|
12
|
Vera C, Tapia V, Vega M and Romero C: Role
of nerve growth factor and its TRKA receptor in normal ovarian and
epithelial ovarian cancer angiogenesis. J Ovarian Res. 10;7:822014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Urzua U, Tapia V, Geraldo MP, Selman A,
Vega M and Romero C: Nerve growth factor stimulates cellular
proliferation of human epithelial ovarian cancer. Horm Metab Res.
44:656–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bussard KM, Mutkus L, Stumpf K,
Gomez-Manzano C and Marini FC: Tumor-associated stromal cells as
key contributors to the tumor microenvironment. Breast Cancer Res.
18:842016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balkwill FR, Capasso M and Hagemann T: The
tumor microenvironment at a glance. J Cell Sci. 125:5591–5596.
2012. View Article : Google Scholar
|
|
16
|
Mahdi AA, Rizvi SH and Parveen A: Role of
endoplasmic reticulum stress and unfolded protein responses in
health and diseases. Indian J Clin Biochem. 31:127–137. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mori K: The unfolded protein response: The
dawn of a new field. Proc Jpn Acad, Ser B Phys Biol Sci.
91:469–480. 2015. View Article : Google Scholar
|
|
18
|
Vandewynckel YP, Laukens D, Geerts A,
Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F and
Van Vlierberghe H: The paradox of the unfolded protein response in
cancer. Anticancer Res. 33:4683–4694. 2013.PubMed/NCBI
|
|
19
|
Sovolyova N, Healy S, Samali A and Logue
SE: Stressed to death: mechanisms of ER stress-induced cell death.
Biol Chem. 395:1–13. 2014. View Article : Google Scholar
|
|
20
|
Yang Y, Li XJ, Chen Z, Zhu XX, Wang J,
Zhang LB, Qiang L, Ma YJ, Li ZY, Guo QL, et al: Wogonin induced
calreticulin/annexin A1 exposure dictates the immunogenicity of
cancer cells in a PERK/AKT dependent manner. PLoS One.
7:e508112012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holaska JM, Black BE, Love DC, Hanover JA,
Leszyk J and Paschal BM: Calreticulin Is a receptor for nuclear
export. J Cell Biol. 152:127–140. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramesh BS, Giorgakis E, Lopez-Davila V,
Dashtarzheneha AK and Loizidou M: Detection of cell surface
calreticulin as a potential cancer biomarker using near-infrared
emitting gold nanoclusters. Nanotechnology. 27:2851012016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu YC, Weng WC and Lee H: Functional roles
of calreticulin in cancer biology. BioMed Res Int. 2015:5265242015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zamanian M, Qader Hamadneh LA,
Veerakumarasivam A, Abdul Rahman S, Shohaimi S and Rosli R:
Calreticulin mediates an invasive breast cancer phenotype through
the transcriptional dysregulation of p53 and MAPK pathways. Cancer
Cell Int. 16:562016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sheng W, Chen C, Dong M, Zhou J, Liu Q,
Dong Q and Li F: Overexpression of calreticulin contributes to the
development and progression of pancreatic cancer. J Cell Physiol.
229:887–897. 2014. View Article : Google Scholar
|
|
26
|
Chiang WF, Hwang TZ, Hour TC, Wang LH,
Chiu CC, Chen HR, Wu YJ, Wang CC, Wang LF, Chien CY, et al:
Calreticulin, an endoplasmic reticulum-resident protein, is highly
expressed and essential for cell proliferation and migration in
oral squamous cell carcinoma. Oral Oncol. 49:534–541. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shu Q, Li W, Li H and Sun G: Vasostatin
inhibits VEGF-induced endothelial cell proliferation, tube
formation and induces cell apoptosis under oxygen deprivation. Int
J Mol Sci. 15:6019–6030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wiersma VR, Michalak M, Abdullah TM,
Bremer E and Eggleton P: Mechanisms of translocation of ER
chaperones to the cell surface and immunomodulatory Roles in cancer
and autoimmunity. Front Oncol. 5:72015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu SP, Wang ZG, Zhao YZ, Wu J, Shi HX, Ye
LB, Wu FZ, Cheng Y, Zhang HY, He S, et al: Gelatin nanostructured
lipid carriers incorporating nerve growth factor inhibit
endoplasmic reticulum stress-induced apoptosis and improve recovery
in spinal cord injury. Mol Neurobiol. 53:4375–4386. 2016.
View Article : Google Scholar
|
|
30
|
Wei K, Liu L, Xie F, Hao X, Luo J and Min
S: Nerve growth factor protects the ischemic heart via attenuation
of the endoplasmic reticulum stress induced apoptosis by activation
of phosphatidylinositol 3-kinase. Int J Med Sci. 12:83–91. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vera C, Tapia V, Kohan K, Gabler F,
Ferreira A, Selman A, Vega M and Romero C: Nerve growth factor
induces the expression of chaperone protein calreticulin in human
epithelial ovarian cells. Horm Metab Res. 44:639–643. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Campos X, Muñoz Y, Selman A, Yazigi R,
Moyano L, Weinstein-Oppenheimer C, Lara HE and Romero C: Nerve
growth factor and its high-affinity receptor trkA participate in
the control of vascular endothelial growth factor expression in
epithelial ovarian cancer. Gynecol Oncol. 104:168–175. 2007.
View Article : Google Scholar
|
|
33
|
Martins I, Kepp O, Schlemmer F, Adjemian
S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N,
et al: Restoration of the immunogenicity of cisplatin-induced
cancer cell death by endoplasmic reticulum stress. Oncogene.
30:1147–1158. 2011. View Article : Google Scholar
|
|
34
|
Zuppini A, Groenendyk J, Cormack LA, Shore
G, Opas M, Bleackley RC and Michalak M: Calnexin deficiency and
endoplasmic reticulum stress-induced apoptosis. Biochemistry.
41:2850–2858. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kepp O, Galluzzi L, Giordanetto F,
Tesniere A, Vitale I, Martins I, Schlemmer F, Adjemian S, Zitvogel
L and Kroemer G: Disruption of the PP1/GADD34 complex induces
calreticulin exposure. Cell Cycle. 8:3971–3977. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hobro AJ and Smith NI: An evaluation of
fixation methods: Spatial and compositional cellular changes
observed by Raman imaging. Vib Spectrosc. In press.
|
|
37
|
Milner RE, Baksh S, Shemanko C, Carpenter
MR, Smillie L, Vance JE, Opas M and Michalak M: Calreticulin, and
not calsequestrin, is the major calcium binding protein of smooth
muscle sarcoplasmic reticulum and liver endoplasmic reticulum. J
Biol Chem. 266:7155–7165. 1991.PubMed/NCBI
|
|
38
|
Parmar T, Nimbkar-Joshi S, Katkam RR,
Gadkar-Sable S, Chaudhari U, Manjramkar DD, Savardekar L, Jacob S,
Puri CP and Sachdeva G: Differential expression of calreticulin, a
reticuloplasmin in primate endometrium. Hum Reprod. 24:2205–2216.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang WA, Groenendyk J and Michalak M:
Calreticulin signaling in health and disease. Int J Biochem Cell
Biol. 44:842–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zamanian M, Veerakumarasivam A, Abdullah S
and Rosli R: Calreticulin and cancer. Pathol Oncol Res. 19:149–154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bian JH, Ghosh TK, Wang JC and Gill DL:
Identification of intracellular calcium pools. Selective
modification by thapsigargin. J Biol Chem. 15;266:8801–8806.
1991.PubMed/NCBI
|
|
42
|
Posner LE, Dukart G, Goldberg J, Bernstein
T and Cartwright K: Mitoxantrone: An overview of safety and
toxicity. Invest New Drugs. 3:123–132. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jackson AL, Eisenhauer EL and Herzog TJ:
Emerging therapies: Angiogenesis inhibitors for ovarian cancer.
Expert Opin Emerg Drugs. 20:331–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
